Quad Screen as a Predictor of Adverse Pregnancy Outcome

Objective: To estimate the effect of second-trimester levels of maternal serum alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG), unconjugated estriol (uE3), and inhibin A (the quad screen) on obstetric complications by using a large, prospectively collected database (the FASTER database). Methods: The FASTER trial was a multicenter study that evaluated first- and second-trimester screening programs for aneuploidy in women with singleton pregnancies. As part of this trial, patients had a quad screen drawn at 15–18 6/7 weeks. We analyzed the data to identify associations between the quad screen markers and preterm birth, intrauterine growth restriction, preeclampsia, and fetal loss. Our analysis was performed by evaluating the performance characteristics of quad screen markers individually and in combination. Crude and adjusted effects were estimated by multivariable logistic regression analysis. Patients with fetal anomalies were excluded from the analysis. Results: We analyzed data from 33,145 pregnancies. We identified numerous associations between the markers and the adverse outcomes. There was a relatively low, but often significant, risk of having an adverse pregnancy complication if a patient had a single abnormal marker. However, the risk of having an adverse outcome increased significantly if a patient had 2 or more abnormal markers. The sensitivity and positive predictive values using combinations of markers is relatively low, although superior to using individual markers. Conclusion: These data suggest that components of the quad screen may prove useful in predicting adverse obstetric outcomes. We also showed that the total number and specific combinations of abnormal markers are most useful in predicting the risk of adverse perinatal outcome. Level of Evidence: II-2

[1]  D. Ellwood,et al.  Doppler investigation of uteroplacental blood flow resistance in the second trimester: a screening study for pre‐eclampsia and intrauterine growth retardation , 1992, British journal of obstetrics and gynaecology.

[2]  D. Nyberg,et al.  Elevated maternal serum alpha-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. , 1992, American journal of obstetrics and gynecology.

[3]  D. Kanon,et al.  Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. , 1992, Radiology.

[4]  L. Boots,et al.  Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. , 1994, American journal of obstetrics and gynecology.

[5]  R. North,et al.  Uterine Artery Doppler Flow Velocity Waveforms in the Second Trimester for the Prediction of Preeclampsia and Fetal Growth Retardation , 1994, Obstetrics and gynecology.

[6]  E. Jauniaux,et al.  MATERNAL SERUM TESTING FOR ALPHA‐FETOPROTEIN AND HUMAN CHORIONIC GONADOTROPIN IN HIGH‐RISK PREGNANCIES , 1996, Prenatal diagnosis.

[7]  J. Himes,et al.  A United States National Reference for Fetal Growth , 1996, Obstetrics and gynecology.

[8]  L. Cusmano,et al.  Association of Low Unconjugated Estriol in the Second Trimester and Adverse Pregnancy Outcome , 1998, Obstetrics and gynecology.

[9]  Y Yaron,et al.  Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. , 1999, American journal of obstetrics and gynecology.

[10]  J. Canick,et al.  Second-Trimester Levels of Maternal Serum Human Chorionic Gonadotropin and Inhibin A as Predictors of Preeclampsia in the Third Trimester of Pregnancy , 2000, The Journal of the Society for Gynecologic Investigation: JSGI.

[11]  K. Harrington,et al.  Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of pre-eclampsia. , 2000, Placenta.

[12]  M. Melbye,et al.  Second‐Trimester Maternal Serum Alpha‐Fetoprotein and Risk of Adverse Pregnancy Outcome , 2001, Obstetrics and gynecology.

[13]  Association Between Maternal Serum Alpha‐Fetoprotein and Adverse Outcomes in Pregnancies With Placenta Previa , 2001, Obstetrics and gynecology.

[14]  K. Nicolaides,et al.  Multicenter screening for pre‐eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[15]  K. Nicolaides,et al.  Comparison of color Doppler uterine artery indices in a population at high risk for adverse outcome at 24 weeks' gestation , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[16]  L. Dodds,et al.  Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. , 2003, American journal of obstetrics and gynecology.

[17]  Tianhua Huang,et al.  Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. , 2003, American journal of obstetrics and gynecology.

[18]  F. Malone,et al.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). , 2004, American journal of obstetrics and gynecology.

[19]  S. Ural,et al.  Abnormal multiple marker screens are associated with adverse perinatal outcomes in cases of intrauterine growth restriction. , 2004, American journal of obstetrics and gynecology.